Alice T. Shaw

Prior to that, Dr. Shaw was the director of the Center for Thoracic Cancers at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Shaw has performed clinical and translational research. Her clinical research has focused on subsets of NSCLC that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research has focused on understanding and making clear the mechanisms of resistance to targeted therapies to develop novel combination treatment strategies. Dr. Shaw’s research has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori®) for patients with ALK or ROS1 rearrangements, and ceritinb (Zykadia®) and alectinib (Alecensa®) for patients with crizotinib-resistant, ALK-rearranged NSCLC.